Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Ref Type||Journal Article|
|Authors||Moreira RB, Peixoto RD, de Sousa Cruz MR|
|Title||Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification.|
|Journal||Case reports in oncology|
|Abstract Text||A considerable number of patients with metastatic colorectal cancer progress after exhausting all approved standard therapies but maintain an adequate performance status and could be candidates for further treatment. We aim at reviewing our experience with sorafenib treatment of a patient with FLT3 mutation in refractory metastatic colorectal cancer.Treatment with sorafenib of a patient with metastatic colorectal cancer and FLT3 translocation who had previously been heavily treated.The patient with metastatic colorectal cancer, aged 51 years, showed significant symptomatic and laboratory improvement with sorafenib treatment (400 mg twice daily).The presented case illustrates how an aggressive and refractory colorectal tumor may respond well to targeted therapy.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 amp||colorectal cancer||predicted - sensitive||Sorafenib||Case Reports/Case Series||Actionable||In a clinical case study, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357).||25848357|